Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 7/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.63 |
| ▸ | SLC22A12 | Q96S37 | 6/20 | 0.61 |
| ▸ | EYA3 | Q99504 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | TTR | P02766 | 2/20 | 0.60 |
| ▸ | PGR | P06401 | 2/20 | 0.60 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.60 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.60 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.60 |
| ▸ | HTR1A | P08908 | 1/20 | 0.60 |
| ▸ | DRD1 | P21728 | 1/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.60 |
| ▸ | PDE4A | P27815 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1287533 | 0.90 | CYP2C19 (0.73) | CYP2C19CYP2C9SLC22A12EYA3MEN1 | |
| SCHEMBL11847420 | 0.88 | EYA3 (0.64) | CYP2C9EYA3TTRNR1H4THRB | |
| SCHEMBL9444764 | 0.86 | NR1H4 (0.69) | CYP2C19CYP2C9SLC22A12EYA3MEN1 | |
| SCHEMBL1287462 | 0.86 | CYP2C9 (0.83) | CYP2C19CYP2C9SLC22A12EYA3MEN1 | |
| SCHEMBL6338280 | 0.83 | EYA3 (0.73) | CYP2C19CYP2C9SLC22A12EYA3MEN1 | |
| SCHEMBL1287913 | 0.82 | EYA3 (0.81) | CYP2C19CYP2C9SLC22A12EYA3MEN1 | |
| SCHEMBL27935343 | 0.81 | EYA3 (0.77) | CYP2C19CYP2C9SLC22A12EYA3MEN1 | |
| SCHEMBL1287556 | 0.80 | CYP2C19 (1.00) | CYP2C19CYP2C9SLC22A12EYA3MEN1 | |
| SCHEMBL11673894 | 0.80 | L3MBTL1 (0.69) | CYP2C19CYP2C9MEN1KMT2ALMNA | |
| SCHEMBL1288122 | 0.80 | EYA3 (0.70) | CYP2C19CYP2C9SLC22A12EYA3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005750-B2 | Developing potent urate transporter inhibitors: compounds designed for their uricosuric action | J-PHARMA CO., LTD. (JP) | 2018-06-26 | — | — | US | disclosed |
| US-20130225673-A1 | DEVELOPING POTENT URATE TRANSPORTER INHIBITORS: COMPOUNDS DESIGNED FOR THEIR URICOSURIC ACTION | J-PHARMA CO., LTD. (JP) | 2013-08-29 | — | — | US | disclosed |
| WO-2012048058-A2 | DEVELOPING POTENT URATE TRANSPORTER INHIBITORS: COMPOUNDS DESIGNED FOR THEIR URICOSURIC ACTION | J-PHARMA CO., LTD. (JP) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005750-B2 | Developing potent urate transporter inhibitors: compounds designed for their uricosuric action | SLCO2B1, SLCO2A1, SLC10A6 | CYP2C19 269/4885CYP2C9 203/4885SLC22A12 19/4885 |
| US-20130225673-A1 | DEVELOPING POTENT URATE TRANSPORTER INHIBITORS: COMPOUNDS DESIGNED FOR THEIR URICOSURIC ACTION | SLCO2B1, SLCO2A1, SLC10A6 | CYP2C19 269/4885CYP2C9 203/4885SLC22A12 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.